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The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung can-
cer (NSCLC). However, some mutations confer resistance to current available agents, especially the fre-
quently occurring T790M mutation. In the current study, we have examined, in a NSCLC cell line
H1975 containing both L858R and T790M mutations, the effect of T790M-speciﬁc-siRNAs versus other
EGFR-speciﬁc-siRNAs. T790M-speciﬁc-siRNAs were able to inhibit T790M and EGFR mRNA, to reduce
EGFR protein expression, as well as to reduce the cell growth and induce cell caspase activity in
H1975 cells. However, this effect showed less potency compared to the other EGFR-speciﬁc-siRNAs.
EGFR-speciﬁc-siRNAs strongly inhibited cell growth and induced apoptosis in H358, H1650, H292,
HCC827 and also in H1975 cells, which showed weak response to tyrosine kinase inhibitors (TKIs) or
cetuximab. The addition of T790M-speciﬁc-siRNAs could rescue the sensitivity of T790M mutant
H1975 cells to TKIs. The combination of T790M-speciﬁc-siRNAs and cetuximab also additively enhanced
cell growth inhibition and induction of apoptosis in H1975 cells. Among the anti-EGFR agents tested, the
strongest biological effect was observed when afatinib was combined with T790M-speciﬁc-siRNAs. Afat-
inib also offered extra effect when combined with cetuximab in H1975 cells. In conclusion, knock-down
of T790M transcript by siRNAs further decreases the cell growth of T790M mutant lung cancer cells that
are treated with TKIs or cetuximab. The combination of a potent, irreversible kinase inhibitor such as
afatinib, with T790M-speciﬁc-siRNAs should be further investigated as a new strategy in the treatment
of lung cancer containing the resistant T790M mutation.
 2012 Elsevier Inc. All rights reserved.1. Background
Lung cancer is one of the most frequent neoplasm worldwide
and about 85–90% of lung cancer is non-small cell lung cancer
(NSCLC) [1]. Activating mutations in the kinase domain of epider-
mal growth factor receptor (EGFR) in NSCLC commonly arise as
in-frame deletions in exon 19 and L858R exon 21 base substitution,
and confer sensitivity to the reversible tyrosine kinase inhibitors
(TKIs) [2,3]. Despite initial responses, NSCLCs driven by EGFR acti-
vating mutations inevitably develop resistance to these TKIs. An
acquired substitutionmutation (T790M) emerges in approximately
50% of EGFR-mutated patients with TKI resistance [4]. The threo-
nine to methionine change at the 790 amino acid ‘‘gatekeeper’’ res-
idue in the EGFR kinase domain has been shown to confer
resistance by increasing the afﬁnity for ATP, compromising the po-ll rights reserved.
UZ Brussel, Vrije Universiteit
um. Fax: +32 2 4776210.
e Grève).tency of reversible TKIs [5]. In these T790M-harboring cells, inhibi-
tion of EGFR by currently available second-generation EGFR-TKIs is
still not sufﬁcient to physiologically prevent the emergence of cells
that are dependent on EGFR signaling [6]. For instance, afatinib
(BIBW 2992, Boehringer Ingelheim GmbH), a panHER inhibitor of
EGFR, HER2 and HER4 kinases, retains some activity in tumors with
a T790M mutation. However, afatinib showed limited efﬁcacy in
NSCLC with T790M [7]. Therefore, strategies to overcome TKI resis-
tance remain practical needs in order to prolong survival of pa-
tients with NSCLC. RNA interference (RNAi) has provided a
powerful tool with which to modulate gene expression for the
study of gene function. Several reports described effects of EGFR-
targeted RNAi to inhibit cell growth [3,4,8–10], however attempts
to knock-down the T790M-containing allele (using shRNA con-
structs) were unsuccessful [4]. In the current study we have for
the ﬁrst time investigated the combined effect of RNAi targeting
T790M mRNA with T790M-speciﬁc-siRNAs, and inactivation of
EGFR signaling using different TKIs or the monoclonal antibody
cetuximab in the cell line H1975 that carries the T790M mutation.
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2.1. siRNAs, cell lines and reagents
Eight siRNAs out of 21 candidate sequences containing the
T790M mutation were selected by applying algorithms from Mau-
rice HO Rational siRNA design (http://ihome.ust.hk/~bokcmho/siR-
NA/siRNA.html), Dharmacon (http://www.dharmacon.com),
Reynolds [11], Ui-Tei [12] and Jagla [13]. Eight siRNAs targeting
wild type (wt) EGFR sequences were designed using algorithms
from Invitrogen, Eurogentec, or Dharmacon or were modiﬁed from
the literature (Table 1). All siRNAs were purchased from Eurogen-
tec (Liege, Belgium). The glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) positive control siRNA (used in preliminary
experiments to optimize transfection efﬁciency, data not shown)
was from Invitrogen (Merelbeke, Belgium). The negative control
siRNA was a proprietary sequence that does not correspond to
any eukaryotic gene (Liege, Belgium). The siRNA duplexes with
the ﬁnal concentration 200 nM (for siRNA pool, 50 nM of each indi-
vidual siRNA were used) were transiently transfected using lipo-
fectamine™ 2000 as described previously [14]. The information
about the cell lines and preparation for different anti-EGFR agents
were described previously [14]. Each experiment was performed at
least in triplicate and three times independently.2.2. RT-qPCR and Western blot analysis
RNA isolation, normalization, real time RT-qPCR for T790M,
EGFR and GAPDH and western blot were as described previously
[14–16]. The following primary antibodies were used: EGFR (CellTable 1
EGFR siRNAs used in the study.
Name of siRNA Exon Sequence
EGFR siRNA486 2–3 GACCATCCAGGAGGTGG
EGFR siRNA604 3 GCAGTCTTATCTAACTAT
EGFR siRNA752 4 GCAGTGACTTTCTCAGCA
EGFR siRNA1247 8–9 GCAAAGTGTGTAACGGA
EGFR siRNA1608 12 GGAGATAAGTGATGGAG
EGFR siRNA2654 20 GGGAACACAAAGACAAT
EGFR siRNA2708 20–21 TCGCAAAGGGCATGAAC
EGFR siRNA4765 28 AGAATGTGGAATACCTA
Scrambled EGFR siRNA486 GAGGTTAGCTGGGTCCC
Scrambled EGFR siRNA604 GCATTGTCATTAAACGCA
Scrambled EGFR siRNA752 GGCTAAGCTCGCTATTAC
Scrambled EGFR siRNA1247 GGTGATTAGGTTATAAA
T790M siRNA2596 20 TCCACCGTGCAGCTCATC
T790M siRNA2597 20 CCACCGTGCAGCTCATCA
T790M siRNA2600 20 CCGTGCAGCTCATCATGC
T790M siRNA2601 20 CGTGCAGCTCATCATGCA
T790M siRNA2603 20 TGCAGCTCATCATGCAGC
T790M siRNA2607 20 AGCTCATCATGCAGCTCA
T790M siRNA2608 20 GCTCATCATGCAGCTCAT









Wt for T790MsiRNA2603, EGFRwtRNA2603 20 TGCAGCTCATCACGCAG
Wt for T790MsiRNA2608, EGFRwtRNA2608 20 GCTCATCACGCAGCTCAT
⁄, Modiﬁed from Ref. [4].
4, Different siRNA design algorithms.
q, By http://www.sirnawizard.com/scrambled.php.
NA, not applicable.Signaling), phospho-EGFR (Tyr1173, clone 9H2, Upstate), phos-
pho-AKT/PKB (pS473, Invitrogen), phospho-ERK1/2 (pTpY185/
187, Invitrogen), phospho-STAT3 (Tyr705, 3E2, Cell Signaling),
phospho-STAT5 (pY694, BD Biosciences) and b-actin (Sigma–Al-
drich N.V.).2.3. Cell functional detections
Cell growth was assessed using a colorimetric tetrazolium assay
(substrate MTS, CellTiter96 AQueous One Solution Cell Prolifera-
tion Assay, Promega, Madison, USA). For the siRNAs + TKI/antibody
combinations, siRNA transfection was performed ﬁrst, and 24 h la-
ter the cells were treated with different anti-EGFR agents in the
same wells and incubated for another 72 h. Cell viability was de-
tected by ﬂuorimetric detection of resoruﬁn (CellTiter-Blue Cell
Viability Assay, Promega, Madison, USA). Caspase-3/7 activity
was measured using a synthetic rhodamine labeled caspase-3/7
substrate performed immediately after the detection of viability
on the same wells. The effects on apoptosis and nuclear morphol-
ogy in the cells were assessed by Hoechst 33342 and propidium io-
dide (PI, Sigma–Aldrich N.V. Bornem, Belgium) double ﬂuorescent
chromatin staining. The protocols were as described previously
[14].2.4. Statistical analysis
SPSS19.0 was used for statistical analysis. Values were pre-
sented as the mean ± standard deviation (SD). One-way Analysis
of Variance (ANOVA) test was performed to analyze signiﬁcance
between groups. The Least Signiﬁcant Difference (LSD) method ofLocation and length (nt) Designed by GC content (%)
CTGGTTAT 486–510(25) Invitrogen 56.0
GATGCAA 604–628(25) Invitrogen 36.0
A 752–770(19) Eurogentec 47.4
ATAGGTAT 1247–1271(25) Invitrogen 40.0
AT 1608–1626(19) Eurogentec 42.1
AT 2654–2672(19) Dharmacon 36.8
TA 2708–2726(19) Dharmacon 47.4
AGG 4766–4785(20) ⁄ 40.0
GATCATGA NA(25) q 56.0
ACGTATT NA(25) q 36.0
A NA(19) q 47.4
CGGACAGA NA(25) q 40.0
ATG 2596–2616(21) 4 57.1
TGC 2597–2617(21) 4 61.9
AGC 2600–2620(21) 4 61.9
GCT 2601–2621(21) 4 57.1
TCA 2603–2623(21) 4 52.4
TGC 2607–2627(21) 4 52.4
GCC 2608–2628(21) 4 57.1
TCG 2612–2632(21) 4 57.1
CCT NA(21) q 61.9
CTCA NA(21) q 61.9
AAT NA(21) q 52.4
CCT NA(21) q 57.1
CGC 2597–2617(21) NA 66.7
AGC 2600–2620(21) NA 66.7
CTCA 2603–2623(21) NA 57.1
GCC 2608–2628(21) NA 61.9
G. Chen et al. / Biochemical and Biophysical Research Communications 431 (2013) 623–629 625multiple comparisons was applied when the probability for ANO-
VA was statistically signiﬁcant. Statistical signiﬁcance was deter-
mined at a P < 0.05 level. In the analysis of additivity and
synergism, the theoretical zero-interaction (exactly additive)
dose–response curve for each siRNA + drug combination was cal-
culated by applying the Bliss independence criterion [17]. Determi-
nation of possible synergy was also assessed by the Biosoft
CalcuSyn program (Ferguson, MO, USA). The Combination Index
(CI) was used to express synergism (CI < 1), additive effect
(CI = 1), or antagonism (CI > 1) [18].3. Results
3.1. Effect of T790M and EGFR-speciﬁc-siRNAs on target expression
and malignant phenotype
The effect of eight siRNAs targeting T790M with the highest
scores obtained from different siRNA designing software [11–13]
was ﬁrstly investigated. All eight T790M-speciﬁc-siRNAs could
downregulate T790M mRNA levels (data not shown) and reduce
cell growth (Supplementary Fig. 1A) with variable efﬁcacy in
H1975 cells, whereas the negative siRNA control and scrambled
controls produced little or no effect (Supplementary Fig. 1B). The
most effective siRNAs targeting T790M (T790MsiRNA2597, 2600,
2603, 2608) were selected to form a pool for subsequent experi-
ments. Likewise, eight individual EGFR-speciﬁc-siRNAs corre-
sponding to different exons were designed or modiﬁed. Among
these eight different EGFR-speciﬁc-siRNAs that were assessed for
their ability to reduce EGFR mRNA levels and inhibit cell prolifera-
tion in different NSCLC cell lines, four were chosen to compose a
siRNA pool (EGFRsiRNA486, 604, 752, 1247).Fig. 1. Effects on protein downregulation and cell proliferation of different siRNAs in H19
speciﬁc-siRNA pool and EGFR-speciﬁc-siRNA pool. Antibodies included phosphorylated (
control, N: negative siRNA control, E: EGFR-speciﬁc-siRNA pool, T: T790M-speciﬁc-siRN
individual T790M-speciﬁc-siRNAs or a pool. ⁄P < 0.05 and ⁄⁄P < 0.01 compared to blank
proliferation with EGFR-speciﬁc-siRNAs or a pool.In H1975 cells, siRNAs targeting the T790M mutation were able
to knock-down the T790M transcript (from 76% to 85%), as de-
tected 96 h post-transfection by the transcript-speciﬁc RT-qPCR as-
say which we set up previously. This assay allows to detect as little
as 1% mutant transcripts in a wt background [15]. The T790M siR-
NA pool offered no extra knock-down effect with the knock-down
ratio of 79 ± 2%. The siRNAs targeting wt sequences were able to
knock-down the EGFR transcript in different NSCLC cell lines. The
EGFR siRNA pool was more potent to downregulate the EGFR
mRNA levels (data not shown). The EGFR-speciﬁc-siRNAs also af-
fected T790M transcript levels in H1975 cells, although differen-
tially and much weaker than the effect of EGFR-speciﬁc-siRNAs
knocking-down of wt EGFR mRNA or T790M-speciﬁc-siRNAs
downregulating T790M transcripts (data not shown).
EGFR protein expression in different cell lines transfected with
EGFR-speciﬁc-siRNAs was severely reduced. The EGFR-speciﬁc-siR-
NA pool downregulated the EGFR protein level more potently than
single siRNA (data not shown). The knock-down achieved almost
the same magnitude in all cell lines studied, and was independent
on the presence or absence of the T790Mmutation. The siRNAs tar-
geting T790M could also down-regulate the EGFR protein expres-
sion slightly in H1975 cells, but less than the wt EGFR-speciﬁc
siRNAs (Fig. 1A).
A colorimetric MTS tetrazolium assay revealed that there was a
time and dose dependent reduction of up to 25% of cell growth in
H1975 cells with T790M-speciﬁc-siRNAs. Consistent with the
mRNA level, the effect of T790M-speciﬁc-siRNA pool was equiva-
lent to the single siRNA (Fig. 1B and C). The T790M-speciﬁc-siRNAs
had little inﬂuence on the cell proliferation of other NSCLC cell
lines (H358, H1650, H292, HCC827, Supplementary Fig. 2). The
inhibition ratio of cell growth caused by single EGFR-speciﬁc-siR-
NAs in H1975 cells could reach 30%. The inhibition effect was much75 cells. (A) Immunoblot analysis of H1975 cells 96 h post-transfection with T790M-
p-) EGFR, total (t-) EGFR, p-ERK1/2, p-AKT, p-STAT3, p-STAT5 and b-actin. M: mock
A. (B) Dose-dependent effect on proliferation. (C) H1975 cells were treated with
control and negative control at the same time point. (D) Dose-dependent effect on
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than two-fold stronger compared to the single siRNA (Figs. 1D
and 2A). To verify these results, the effect on viability was assessed
using a ﬂuorimetric resoruﬁn viability assay and by microscopic
counting of viable (Hoechst 33342 positive/PI negative) cells
(Figs. 2B and 3). In both assays the results largely mirrored the
MTS tetrazolium assay results. EGFR siRNA pool also yielded a
stronger effect on cell growth suppression in the cell lines without
T790M mutations compared to single siRNA (Supplementary
Fig. 3).
Of particular interest is the capacity of these siRNAs to induce
apoptosis. The tetrazolium assay was multiplexed with a ﬂuores-
cent caspase-3/7 assay. The results show a dose dependent in-
crease of the caspase-3/7 signal in H1975 cells with all T790M-
speciﬁc-siRNAs. The effect of the T790M-speciﬁc-siRNA pool was
slightly stronger than the single siRNA (Fig. 2C). A time dependent
manner was also observed to induce caspase-3/7 activity in H1975
cells with T790M-speciﬁc-siRNAs (Fig. 2D). The effect of caspase
induction was nearly three-fold higher compared to mock control
96 h post-transfection (Fig. 2C and D). This activity was conﬁrmed
by microscopic counting of apoptotic cells with Hoechst 33342 and
PI staining (Fig. 3). The T790M-speciﬁc-siRNAs had little effect on
the caspase activity induction in H358, H1650, H292 and HCC827
cells. The EGFR-speciﬁc-siRNA pool induced more caspase signals
compared to T790M-speciﬁc-siRNA pool in H1975 cells (Fig. 2D).
The EGFR-speciﬁc-siRNA pool also induced caspase-3/7 activity
in other 4 cell lines with different magnitude. The least sensitive
cell line was the H292 cell line (EGFR wt) in which even at the
highest concentration tested and longest time, a three-fold in-
crease in apoptotic rate was not obtained, while in the other cell
lines a three-fold apoptotic rate was reached within 72 h (Supple-Fig. 2. Effects on cell growth and caspase of different siRNAs in H1975 cells. Effect to re
cells. (A) Cell proliferation detected by an MTS assay; (B) Cell viability assessed with a ﬂu
effects with single T790M-speciﬁc-siRNAs or a pool. (D) Time-dependent effects with
compared to blank control and negative control at the same time point.mentary Fig. 4). The T790M-speciﬁc-siRNAs in H1975 cells affect
slightly the downstream pathways: ERK, AKT and STAT. The down-
regulation of these pathways by EGFR-speciﬁc-siRNA was however
much more effective, especially the AKT pathway (Fig. 1A). This
might explain the weaker effect observed with T790M-speciﬁc-
siRNA on cell growth inhibition and apoptosis induction compared
to EGFR-speciﬁc-siRNA treatment in the H1975 cells.
3.2. Effect of adding T790M-speciﬁc-siRNAs to either EGFR TKIs or to
cetuximab
H1975 cells were treated with reversible EGFR TKIs geﬁtinib
and erlotinib, the panHER inhibitor afatinib, or with the monoclo-
nal antibody cetuximab. Afatinib produced a stronger inhibition
(IC50 = 0.9827 ± 0.1784 lM) on cell growth than the reversible
kinase inhibitors geﬁtinib (IC50 = 5.4405 ± 0.3394 lM) and erloti-
nib (IC50 = 6.7519 ± 0.2507 lM), or the monoclonal antibody
cetuximab (IC50 = 2.7994 ± 0.2285lM), as assessed by MTS assay.
The effect of the anti-EGFR agents was also studied using the
ﬂuorimetric resoruﬁn viability assay, yielding analogous results
(data not shown). The combination of T790M-speciﬁc-siRNAs with
TKIs or cetuximab on cell growth in H1975 cells was also studied
using the MTS assay. There was an enhancement of cell growth
inhibition in H1975 cells treated with the T790M-speciﬁc-siR-
NAs + drug combinations compared to single agent. The most
potent combination was the T790M-speciﬁc-siRNAs plus afatinib
(Fig. 4). As can be seen in Fig. 4, addition of T790M-speciﬁc-siRNAs
systematically further reduced cell growth over afatinib alone.
Conversely, by comparing also zero afatinib dose with the samples
treated with afatinib in increasing doses it is also apparent that the
addition of afatinib to siRNA also increases the growth inhibition.duce cell growth by different siRNAs targeting T790M or wild type EGFR in H1975
orimetry. Effect to induce caspase activity by different siRNAs. (C) Dose-dependent
T790M-speciﬁc-siRNA pool and EGFR-speciﬁc-siRNA pool. ⁄P < 0.05 and ⁄⁄P < 0.01
Fig. 3. Effects of different siRNAs on cell growth and apoptosis as evidenced by Hoechst 33342 and propidium iodide (PI) double ﬂuorescent staining. H1975 cells (104 cells
per well) were plated in 96-well-plate and treated on the second day with T790M or EGFR-speciﬁc-siRNA pool (200 nM) for 96 h. Live cells and apoptotic cells were detected
with Hoechst 33342 and PI double ﬂuorescent staining. The number of apoptotic cells was normalized to the number of live cells in the same well 200.
Fig. 4. Combinational effects of different anti-EGFR agent with T790M-spediﬁc-siRNAs on cell growth inhibition in H1975 cells. H1975 cells (104 cells per well) were plated in
96-well-plate and transfected on the second day with T790M-speciﬁc-siRNA pool (200 nM). Different anti-EGFR agents were added 24 h post siRNA transfection and
incubated for another 72 h. ⁄P < 0.05 and ⁄⁄P < 0.01, compared to each agent alone.
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was calculated [17]. The results unambiguously show that the
combined inhibition of proliferation is additive for all the combina-
tions, since the combination indexes are close to or equal to one(data not shown). There was also a potentiation of apoptosis in
H1975 cells treated with the T790M-speciﬁc-siRNAs + drug combi-
nations versus single agent alone (Supplementary Fig. 5). The com-
binational effect was only clearly observed at doses of 10 lM of
628 G. Chen et al. / Biochemical and Biophysical Research Communications 431 (2013) 623–629erlotinib and cetuximab, and between 1 and 10 lM of geﬁtinib. The
strongest combinational activity was observed at supra micro mo-
lar doses of afatinib. The combination of afatinib and cetuximab
has been reported to overcome resistance due to T790M mutation
both in vivo [19] as well as clinically [20]. We then tested the com-
binational effect of afatinib and cetuximab on H1975 cells in vitro.
The addition of afatinib further enhanced the effect of cetuximab to
inhibit cell growth. However, the effect was additive, as analyzed
by the combination index (Supplementary Figs. 6 and 7A). Mean-
while, afatinib increased the effect of cetuximab to induce apopto-
sis (Supplementary Fig. 7B).
4. Discussion
In a previous study we have shown that the addition of EGFR-
speciﬁc-siRNA to TKIs or cetuximab increases the therapeutic ef-
fects in different NSCLC cell lines with various genomic back-
ground [14]. Besides that, only a few publications report on the
biological effects of RNAi targeting EGFR on lung cancer cells
[3,4,8–10]. In the present study, we further enhanced the effect
of EGFR-speciﬁc-siRNAs by introducing a siRNA pool consisting of
four individual siRNAs. The EGFR-speciﬁc-siRNA pool led to a much
more potent activity in downregulating EGFR mRNA, and protein,
as well as in reducing cell growth and inducing cell apoptosis, com-
pared to single siRNA, regardless of driver gene background in dif-
ferent cell lines.
At least half of the acquired resistance to EGFR-TKIs in advanced
NSCLC patients is considered to be mediated by the ‘‘gatekeeper’’
mutation T790M [14]. Speciﬁcally targeting this T790M mutation,
using RNAi, has been studied once. Engelman et al. [4] generated
six shRNA constructs to speciﬁcally downregulate the T790M-con-
taining allele. None of the constructs was found to effectively
downregulate the EGFR (shRNA sequences were however not spec-
iﬁed). In the present study, siRNAs speciﬁcally targeting the T790M
mutation decreased cell growth and induced apoptosis signals to
various degrees. They also modestly downregulated downstream
signaling (p-AKT, p-ERK1/2 and p-STAT5) in H1975 cells, but much
weaker compared to EGFR wt siRNAs. Effects were also detectable
at the mRNA level, by real-time RT-qPCR. With a T790M-speciﬁc-
siRNA pool, approximately 80% T790MmRNA knock-down was ob-
tained, based on our transcript-speciﬁc real time RT-qPCR assay.
However, in contrast to what was observed with the EGFR-spe-
ciﬁc-siRNA pool, the effect of the T790M-speciﬁc-siRNA pool was
not superior compared to single siRNA. The discrepancy between
T790M-speciﬁc-siRNA pool and EGFR-speciﬁc-siRNA pool could
be explained by the different range over the EGFR sequence cov-
ered by these two siRNA pools. The T790M-speciﬁc-siRNA pool in-
cludes T790MsiRNA2597, 2600, 2603 and 2608, which covers only
31 bp length (from 2597th to 2628th). Whereas the EGFR-speciﬁc-
siRNA pool covers 786 bp from exon 2 to exon 9 (from 486th to
1271th). None of the T790M-speciﬁc-siRNAs tested here favored
knock-down of T790M over wt EGFR transcript. However, the
T790M-speciﬁc-siRNAs reduced cell growth and induced cellular
apoptosis in H1975 cells more modestly compared to EGFR-spe-
ciﬁc-siRNAs. However, the T790M-speciﬁc-siRNAs did have a
selective effect against T790M versus other mutant forms of EGFR
or wt EGFR, leading to speciﬁc funtional effects in the cell line
carrying this mutation. This could have advantages for in vivo
application with regard to toxicity.
Anti-EGFR TKIs and antibodies differ in action mechanisms.
However, none of these agents alone does maximally suppress
EGFR signaling, as also shown in our experiments. The combination
of afatinib and cetuximab has been reported to overcome T790M
resistance both preclinically [19] and clinically [20]. Regales et al.
[19] found that dual targeting of EGFR with afatinib and cetuximab
could induce regression of H1975 cell xenografts and thus over-come the major drug resistant T790M mutation. A clinical trial of
combination of afatinib and cetuximab on NSCLC is now ongoing
(ClinicalTrials.gov Identiﬁer: NCT01090011, sponsor: Boehringer
Ingelheim Pharmaceuticals, http://www.clinicaltrials.gov). In the
current study, we tested the combinatorial effect of afatinib and
cetuximab on H1975 cells. The combination of these agents had
a stronger effect on cell growth inhibition and induction of caspase
activity. However, the effect is additive, not synergistic. The less
potent effect in vitro from the combination compared to that
in vivo could be due to the micro-environmental conditions
in vivo. The complement mediated tumor cell killing (CDC) or anti-
body-dependent cell-mediated cytotoxicity (ADCC) could play a vi-
tal role in the in vivo effect of cetuximab. Preclinical results have
already shown that cetuximab has the ability of inducing either
CDC or ADCC by interacting with natural killers (NKs), monocytes
and granulocytes by means of their speciﬁc Fc receptors [21]. The
lack of host responses inﬂuences the effect of cetuximab, thus re-
duces the combinational outcome of cetuximab and afatinib.
Since the T790Mmutation is a main cause of the acquired resis-
tance to ﬁrst generation TKIs, in the present study, we combined
the T790M-speciﬁc-siRNAs with different anti-EGFR agents. The
combined treatment of T790M-speciﬁc-siRNAs and TKIs or anti-
body in H1975 achieved increased tumor cell growth suppression
(max. about 30%, Fig. 4) and increased apoptosis by more than
two-fold (Supplementary Fig. 5). The effect with the different
agents in the different cell lines was additive. Thus, when T790M
is eliminated by RNAi, the sensitivity to TKIs is partially rescued.
The differential sensitivity to the combination paralleled the differ-
ential sensitivities to the TKIs tested or cetuximab alone. Afatinib
with T790M-speciﬁc-siRNAs achieved the strongest combinatorial
effect. Even at very low concentration of afatinib (10–100 nM), the
dual effect on cell growth inhibition and caspase activity induction
was signiﬁcantly more potent compared to the single treatment.
The combination of geﬁtinib, erlotinib or cetuximab with T790M-
speciﬁc-siRNAs had less potent activity.
We conclude that RNA interference by siRNA oligonucleotides
targeting the T790M mutation should be further explored and
developed as a therapeutic modality in the treatment of T790M
mutant lung cancer. The selectivity of these siRNAs for the
T790Mmutant EGFR as opposed to other mutant forms or wt EGFR
could represent an advantage in terms of toxicity. It is not known
whether the concentrations of siRNAs used in the present study
will be achievable in vivo and in the clinic. The most appealing
small molecule to test in a combination strategy with T790M-spe-
ciﬁc-siRNAs would be afatinib, the panHER irreversible inhibitor.
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